01—Abstract
Summary
Summary of the 8-K filed March 11, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. filed a Current Report on Form 8-K reporting the departure of Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer.
The Company announced on March 7, 2025 that her departure was effective the same day. The filing states that her leadership responsibilities will be managed on an interim basis by Aileen Kinsella, the Company's Head of Proprietary Product Sales. The filing contains no financial results, guidance, or quantitative disclosures.
Its only substantive disclosure is this senior commercial leadership change, under Item 5.02. The Company thanked Ms. Reiss-Clark for her contributions and service. The Item 9.01 exhibit list references only the Inline XBRL cover page for the March 7, 2025 Current Report, so no additional financial exhibits are included in this filing.
02—Key points
Key Highlights
- Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, departed the Company effective March 7, 2025.
- Aileen Kinsella, Head of Proprietary Product Sales, will manage the Chief Commercial Officer responsibilities on an interim basis.
- The filing is disclosed under Item 5.02 (Departure of Directors or Certain Officers; Compensatory Arrangements of Certain Officers).
- The filing does not disclose a permanent successor for the Chief Commercial Officer role.
- The filing contains no financial results, guidance, or quantitative information.
- Item 9.01 lists only the Inline XBRL cover page (Exhibit 104) as an exhibit.
03—Questions
Frequently Asked Questions
Who left West Pharmaceutical Services and what was her role?
Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, departed the Company effective March 7, 2025, according to the filing.
Who is handling the commercial leadership responsibilities now?
The filing states that Aileen Kinsella, the Company's Head of Proprietary Product Sales, will manage those responsibilities on an interim basis.
Did the Company name a permanent replacement for the Chief Commercial Officer?
The filing does not mention a permanent successor or a search process for the role.
Does this filing include financial results or guidance?
No. The filing addresses only the officer departure and includes an Inline XBRL cover page as its sole exhibit.
04—Continue